PPM1D mutations silence NAPRT gene expression and confer NAMPT inhibitor sensitivity in glioma - Fons, Nathan R.; Sundaram, Ranjini K.; Breuer, Gregory A.; Peng, Sen; McLean, Ryan L.; Kalathil, Aravind N.; Schmidt, Mark S.; Carvalho, Diana M.; Mackay, Alan; Jones, Chris; Carcaboso, Ángel M.; Nazarian, Javad; et al. (Nature communications, 2019)
Keywords: 13/106; 38/109; 38/15; 38/77; 45/23; 45/41; 45/70; 59/5; 631/67/1922; 631/67/395; 631/67/68/2486; 96/1; Animals; Antineoplastic Agents - pharmacology; Antineoplastic Agents - therapeutic use; Astrocytes; Biosynthesis; Brain Stem Neoplasms - drug therapy; Brain Stem Neoplasms - genetics; Brain Stem Neoplasms - pathology; Brain tumors; Cell Line, Tumor; Child; Children; CpG islands; Cytokines - antagonists & inhibitors; Diffuse Intrinsic Pontine Glioma - drug therapy; Diffuse Intrinsic Pontine Glioma - genetics; Diffuse Intrinsic Pontine Glioma - pathology; DNA Methylation; Epigenetic Repression; Female; Gene expression; Gene Expression Regulation, Neoplastic; Genomes; Glioma; Humanities and Social Sciences; Humans; Inhibitors; Mice; multidisciplinary; Mutation; NAD; Nicotinamide; Nicotinamide phosphoribosyltransferase; Nicotinamide Phosphoribosyltransferase - antagonists & inhibitors; Nicotinamide Phosphoribosyltransferase - genetics; Nicotinamide Phosphoribosyltransferase - metabolism; Nicotinic acid; Pediatrics; Phosphoribosyltransferase; Pons - cytology; Pons - pathology; Primary Cell Culture; Protein phosphatase; Protein Phosphatase 2C - genetics; Protein Phosphatase 2C - metabolism; Science; Science (multidisciplinary); Synthetic Lethal Mutations; Tumors; Xenograft Model Antitumor Assays